Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy.

[1]  Dong‐sheng Guo,et al.  Dual hypoxia-responsive supramolecular complex for cancer target therapy , 2023, Nature communications.

[2]  Kailin Yang,et al.  Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy , 2023, Nature Reviews Clinical Oncology.

[3]  Si-ying Zhou,et al.  CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis , 2023, Scientific reports.

[4]  Brian J. Stevenson,et al.  Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors , 2023, Nature communications.

[5]  M. Edson,et al.  Quantitative intravital imaging for real-time monitoring of pancreatic tumor cell hypoxia and stroma in an orthotopic mouse model , 2023, Science advances.

[6]  J. Irlam,et al.  Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD). , 2023, Journal of Clinical Oncology.

[7]  K. Brodaczewska,et al.  Microenvironment commits breast tumor ECs to dedifferentiation by micro-RNA-200-b-3p regulation and extracellular matrix remodeling , 2023, Frontiers in Cell and Developmental Biology.

[8]  G. Berx,et al.  The epithelial–mesenchymal plasticity landscape: principles of design and mechanisms of regulation , 2023, Nature Reviews Genetics.

[9]  W. Tai,et al.  Bioinformatics Identification of Regulatory Genes and Mechanism Related to Hypoxia-Induced PD-L1 Inhibitor Resistance in Hepatocellular Carcinoma , 2023, International journal of molecular sciences.

[10]  L. Billingham,et al.  Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma , 2023, British Journal of Cancer.

[11]  Shunqing Wang,et al.  Optimal combination of immune checkpoint and senescence molecule predicts adverse outcomes in patients with acute myeloid leukemia , 2023, Annals of medicine.

[12]  A. Griffioen,et al.  Pathological angiogenesis: mechanisms and therapeutic strategies , 2023, Angiogenesis.

[13]  J. Sun,et al.  Self-adaptive nanoassembly enabling turn-on hypoxia illumination and periphery/center closed-loop tumor eradication , 2023, Cell reports. Medicine.

[14]  A. R. Banday,et al.  APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential , 2023, Journal of Hematology & Oncology.

[15]  Carlos Carmona-Fontaine,et al.  Hypoxia potentiates the inflammatory fibroblast phenotype promoted by pancreatic cancer cell-derived cytokines. , 2023, Cancer research.

[16]  S. Chouaib,et al.  Chronic hypoxia is associated with transcriptomic reprogramming and increased genomic instability in cancer cells , 2023, Frontiers in Cell and Developmental Biology.

[17]  YU Peng,et al.  Loss of exosomal miR-200b-3p from hypoxia cancer-associated fibroblasts promotes tumorigenesis and reduces sensitivity to 5-Flourouracil in colorectal cancer via upregulation of ZEB1 and E2F3 , 2023, Cancer Gene Therapy.

[18]  C. Kieda,et al.  Tumour suppressor PTEN activity is differentially inducible by myo‐inositol phosphates , 2023, Journal of cellular and molecular medicine.

[19]  Bo Wu,et al.  Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment , 2023, Molecular Cancer.

[20]  A. Giaccia,et al.  Hypoxia‐mediated regulation of DDX5 through decreased chromatin accessibility and post‐translational targeting restricts R‐loop accumulation , 2023, bioRxiv.

[21]  M. Boutros,et al.  USP47 deubiquitylates Groucho/TLE to promote Wnt–β-catenin signaling , 2023, Science Signaling.

[22]  M. Ducreux,et al.  Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy , 2023, Cancers.

[23]  T. Eubank,et al.  The Underexplored Landscape of Hypoxia-Inducible Factor 2 Alpha and Potential Roles in Tumor Macrophages: A Review , 2023, Oxygen.

[24]  V. Richter,et al.  “Pulsed Hypoxia” Gradually Reprograms Breast Cancer Fibroblasts into Pro-Tumorigenic Cells via Mesenchymal–Epithelial Transition , 2023, International journal of molecular sciences.

[25]  N. Mizushima,et al.  Autophagy genes in biology and disease , 2023, Nature Reviews Genetics.

[26]  Qing Zhang,et al.  Tumor hypoxia: From basic knowledge to therapeutic implications. , 2023, Seminars in cancer biology.

[27]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[28]  Greg M. Delgoffe,et al.  Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity , 2022, Nature Immunology.

[29]  Rebecca A Dagg,et al.  Targeting DNA damage response pathways in cancer , 2022, Nature Reviews Cancer.

[30]  E. Navarro,et al.  Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype , 2022, The Journal of pathology.

[31]  J. Thiery.  Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions , 2022, Exploration of targeted anti-tumor therapy.

[32]  Xuan Liu,et al.  A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses , 2022, Frontiers in Immunology.

[33]  Xiao X. J. Huang,et al.  RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma , 2022, Journal of Experimental & Clinical Cancer Research.

[34]  W. Kaelin.  Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer , 2022, The Journal of clinical investigation.

[35]  Lin Zhao,et al.  The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies , 2022, Molecular Cancer.

[36]  P. Mishra,et al.  Is Epithelial-Mesenchymal Transition a New Roadway in the Pathogenesis of Oral Submucous Fibrosis: A Comprehensive Review , 2022, Cureus.

[37]  Yong-Guang Yang,et al.  The Role of Osteopontin in Tumor Progression Through Tumor-Associated Macrophages , 2022, Frontiers in Oncology.

[38]  Iljin Kim,et al.  Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment , 2022, Cancers.

[39]  H. Denley,et al.  Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature. , 2022, Molecular medicine reports.

[40]  C. Taylor,et al.  The effect of HIF on metabolism and immunity , 2022, Nature Reviews Nephrology.

[41]  Changjing Wang,et al.  Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer , 2022, Frontiers in Genetics.

[42]  V. Adam,et al.  Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape , 2022, Journal of Hematology & Oncology.

[43]  R. Monasson,et al.  Neoantigen quality predicts immunoediting in survivors of pancreatic cancer , 2022, Nature.

[44]  H. Crawford,et al.  Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer , 2022, bioRxiv.

[45]  B. C. Jena,et al.  TGF-β1 induced autophagy in cancer associated fibroblasts during hypoxia contributes EMT and glycolysis via MCT4 upregulation. , 2022, Experimental cell research.

[46]  I. Buvat,et al.  Fibroblast heterogeneity in solid tumors: from single cell analysis to whole-body imaging. , 2022, Seminars in cancer biology.

[47]  H. Mano,et al.  Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  S. Terry,et al.  The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes? , 2022, Frontiers in Immunology.

[49]  Daniele M. Gilkes,et al.  Detection of Hypoxia in Cancer Models: Significance, Challenges, and Advances , 2022, Cells.

[50]  H. Yao,et al.  A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma , 2022, Frontiers in Cell and Developmental Biology.

[51]  Xiao-Li Zhu,et al.  Hypoxia Upregulates NOTCH3 Signaling Pathway to Promote Endothelial-Mesenchymal Transition in Pulmonary Artery Endothelial Cells , 2021, Evidence-based complementary and alternative medicine : eCAM.

[52]  Jian Zhang,et al.  Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma , 2021, Frontiers in Cell and Developmental Biology.

[53]  Hao Chen,et al.  Identification of Hypoxia-Related Molecular Classification and Associated Gene Signature in Oral Squamous Cell Carcinoma , 2021, Frontiers in Oncology.

[54]  G. Semenza.  Heritable disorders of oxygen sensing , 2021, American journal of medical genetics. Part A.

[55]  Junhao Fu,et al.  Role of Ubiquitin-Specific Peptidase 47 in Cancers and Other Diseases , 2021, Frontiers in Cell and Developmental Biology.

[56]  R. Kalluri,et al.  Clinical and therapeutic relevance of cancer-associated fibroblasts , 2021, Nature Reviews Clinical Oncology.

[57]  A. Puisieux,et al.  Cellular Plasticity: A Route to Senescence Exit and Tumorigenesis , 2021, Cancers.

[58]  X. Cui,et al.  Hypoxia‐stimulated ATM activation regulates autophagy‐associated exosome release from cancer‐associated fibroblasts to promote cancer cell invasion , 2021, Journal of extracellular vesicles.

[59]  J Zhang,et al.  Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis , 2021, BMC cancer.

[60]  K. Brodaczewska,et al.  Distinctive Properties of Endothelial Cells from Tumor and Normal Tissue in Human Breast Cancer , 2021, International journal of molecular sciences.

[61]  S. Terry,et al.  The Most Common VHL Point Mutation R167Q in Hereditary VHL Disease Interferes with Cell Plasticity Regulation , 2021, Cancers.

[62]  A. Carnero,et al.  Cellular senescence or stemness: hypoxia flips the coin , 2021, Journal of Experimental & Clinical Cancer Research.

[63]  G. Wang,et al.  Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer , 2021, Molecular therapy oncolytics.

[64]  E. Hammond,et al.  Replication catastrophe induced by cyclic hypoxia leads to increased APOBEC3B activity , 2021, Nucleic acids research.

[65]  Sherine F. Elsawa,et al.  Macrophage Polarization States in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[66]  A. Jetter,et al.  Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors , 2021, Nature Communications.

[67]  B. S. Sørensen,et al.  Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts , 2021, Cancers.

[68]  Yingrui Li,et al.  The regulation of immune checkpoints by the hypoxic tumor microenvironment , 2021, PeerJ.

[69]  Yangyang Bian,et al.  HIF‐1α is necessary for activation and tumour‐promotion effect of cancer‐associated fibroblasts in lung cancer , 2021, Journal of cellular and molecular medicine.

[70]  K. Tomczak,et al.  Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing , 2021, Proceedings of the National Academy of Sciences.

[71]  A. Griffioen,et al.  Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes , 2021, Nature Reviews Clinical Oncology.

[72]  Z. Duan,et al.  Targeting macrophages in cancer immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[73]  K. O'Byrne,et al.  Tumor Hypoxia Drives Genomic Instability , 2021, Frontiers in Cell and Developmental Biology.

[74]  Zhou Lu,et al.  Hypoxia facilitates the proliferation of colorectal cancer cells by inducing cancer-associated fibroblast-derived IL6. , 2021, Neoplasma.

[75]  M. Simons,et al.  The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy , 2021, Nature Reviews Cardiology.

[76]  G. Collet,et al.  Tumour angiogenesis normalized by myo‐inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response , 2021, Journal of cellular and molecular medicine.

[77]  M. Guckenberger,et al.  Tumor Oxygenation by Myo-Inositol Trispyrophosphate Enhances Radiation Response. , 2021, International journal of radiation oncology, biology, physics.

[78]  S. Chouaib,et al.  Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies , 2021, Frontiers in Immunology.

[79]  S. Terry,et al.  Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity? , 2021, Oncoimmunology.

[80]  Linda Ziani,et al.  Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity , 2021, Oncoimmunology.

[81]  M. Black,et al.  Hypoxia theranostics of a human prostate cancer xenograft and the resulting effects on the tumor microenvironment , 2020, Neoplasia.

[82]  A. Giatromanolaki,et al.  Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways. , 2020, Life sciences.

[83]  A. Pircher,et al.  Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment – New Findings and Future Perspectives , 2020, Frontiers in Cell and Developmental Biology.

[84]  M. Tavassoli,et al.  Inside the hypoxic tumour: reprogramming of the DDR and radioresistance , 2020, Cell Death Discovery.

[85]  S. Terry,et al.  Hypoxia-driven intratumor heterogeneity and immune evasion. , 2020, Cancer letters.

[86]  P. Fisher,et al.  Vascular mimicry: Triggers, molecular interactions and in vivo models. , 2020, Advances in cancer research.

[87]  Qian Ning,et al.  Metformin suppresses HIF‐1α expression in cancer‐associated fibroblasts to prevent tumor‐stromal cross talk in breast cancer , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[88]  Li Lei,et al.  Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways , 2020, Journal of immunology research.

[89]  E. Hammarlund.  Harnessing hypoxia as an evolutionary driver of complex multicellularity , 2020, Interface Focus.

[90]  S. Raza,et al.  Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer. , 2020, Cell reports.

[91]  H. Lyng,et al.  Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity , 2020, medRxiv.

[92]  E. Hammond,et al.  Hypoxia-induced SETX links replication stress with the unfolded protein response , 2020, Nature Communications.

[93]  S. Haake,et al.  Hypoxia-induced epithelial to mesenchymal transition in cancer. , 2020, Cancer letters.

[94]  K. Tarte,et al.  Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. , 2020, Cancer discovery.

[95]  P. Buckhaults,et al.  Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer , 2020, Nature Communications.

[96]  D. Ribatti,et al.  Epithelial-Mesenchymal Transition in Cancer: A Historical Overview , 2020, Translational oncology.

[97]  Raymond B. Runyan,et al.  Guidelines and definitions for research on epithelial–mesenchymal transition , 2020, Nature Reviews Molecular Cell Biology.

[98]  V. Budach,et al.  Comparison of GeneChip, nCounter and real-time polymerase chain reaction based gene expressions predicting loco-regional tumour control after primary and postoperative radiochemotherapy in head and neck squamous cell carcinoma. , 2020, The Journal of molecular diagnostics : JMD.

[99]  D. Gewirtz,et al.  Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy , 2020, Cancers.

[100]  A. Gimenez-Roqueplo,et al.  An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma. , 2020, Best practice & research. Clinical endocrinology & metabolism.

[101]  Thea D. Tlsty,et al.  A framework for advancing our understanding of cancer-associated fibroblasts , 2020, Nature Reviews Cancer.

[102]  P. Fasching,et al.  A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial , 2020, Clinical Cancer Research.

[103]  P. Dessen,et al.  Hypoxia increases mutational load of breast cancer cells through frameshift mutations , 2020, Oncoimmunology.

[104]  L. Ivashkiv.  The hypoxia–lactate axis tempers inflammation , 2019, Nature Reviews Immunology.

[105]  Isobel S Okoye,et al.  Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells. , 2019, Life sciences.

[106]  P. Carmeliet,et al.  The metabolic engine of endothelial cells , 2019, Nature metabolism.

[107]  F. Borrego,et al.  NK Cell Metabolism and Tumor Microenvironment , 2019, Front. Immunol..

[108]  B. Ren,et al.  Metabolic regulation of gene expression by histone lactylation , 2019, Nature.

[109]  F. Slevin,et al.  Tumour Hypoxia. , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

[110]  G. Berchem,et al.  Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges , 2019, Cells.

[111]  Zhihong Yang,et al.  Hypoxia Enhances Endothelial Intercellular Adhesion Molecule 1 Protein Level Through Upregulation of Arginase Type II and Mitochondrial Oxidative Stress , 2019, Front. Physiol..

[112]  Zhen Luo,et al.  Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis , 2019, RNA biology.

[113]  Mariella G. Filbin,et al.  An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma , 2019, Cell.

[114]  S. Matosevic,et al.  Immunometabolic Dysfunction of Natural Killer Cells Mediated by the Hypoxia-CD73 Axis in Solid Tumors , 2019, Front. Mol. Biosci..

[115]  P. Glazer,et al.  Impact of hypoxia on DNA repair and genome integrity. , 2019, Mutagenesis.

[116]  L. Galluzzi,et al.  Macrophages and Metabolism in the Tumor Microenvironment. , 2019, Cell metabolism.

[117]  Yalu Zhou,et al.  The transcription factor Slug represses p16Ink4a and regulates murine muscle stem cell aging , 2019, Nature Communications.

[118]  W. Linehan,et al.  The Metabolic Basis of Kidney Cancer. , 2019, Cancer discovery.

[119]  L. Elmore,et al.  Tumor cell escape from therapy‐induced senescence , 2019, Biochemical pharmacology.

[120]  V. Pillarisetty,et al.  Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma , 2019, Clinical and Translational Medicine.

[121]  A. Alimonti,et al.  Cellular Senescence: Aging, Cancer, and Injury. , 2019, Physiological reviews.

[122]  Y. Hayashi,et al.  Hypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer , 2019, Cancer science.

[123]  X. Cui,et al.  Oxidized ATM-mediated glycolysis enhancement in breast cancer-associated fibroblasts contributes to tumor invasion through lactate as metabolic coupling , 2019, EBioMedicine.

[124]  J. Kleeff,et al.  Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma , 2019, The Journal of pathology.

[125]  E. Markert,et al.  Hypoxic cancer–associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling , 2019, Science Signaling.

[126]  P. Boutros,et al.  Divergent mutational processes distinguish hypoxic and normoxic tumours , 2019, Nature Communications.

[127]  Robert Lesurf,et al.  Molecular landmarks of tumor hypoxia across cancer types , 2019, Nature Genetics.

[128]  N. Roewer,et al.  Hypoxia-Induced MicroRNA-212/132 Alter Blood-Brain Barrier Integrity Through Inhibition of Tight Junction-Associated Proteins in Human and Mouse Brain Microvascular Endothelial Cells , 2019, Translational Stroke Research.

[129]  Ke Chen,et al.  Hypoxia‐driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial–mesenchymal transition and cancer stem cell‐like properties by modulating forkhead box protein M1 , 2018, Molecular oncology.

[130]  B. Gallez,et al.  Impact of myo‐inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models , 2018, Journal of cellular and molecular medicine.

[131]  Åsa K. Björklund,et al.  Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing , 2018, Nature Communications.

[132]  L. Liang,et al.  The role of the hypoxia‐Nrp‐1 axis in the activation of M2‐like tumor‐associated macrophages in the tumor microenvironment of cervical cancer , 2018, Molecular carcinogenesis.

[133]  J. Utikal,et al.  Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression , 2018, British Journal of Cancer.

[134]  S. Matosevic,et al.  Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells , 2018, Front. Immunol..

[135]  S. Matosevic,et al.  Adenosinergic Signaling Alters Natural Killer Cell Functional Responses , 2018, Front. Immunol..

[136]  L. Moretta,et al.  Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration , 2018, Front. Immunol..

[137]  M. McBurney,et al.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade , 2018, The Journal of clinical investigation.

[138]  Jian Li,et al.  The Expression of FAP in Hepatocellular Carcinoma Cells is Induced by Hypoxia and Correlates with Poor Clinical Outcomes , 2018, Journal of Cancer.

[139]  L. Emens,et al.  Targeting adenosine for cancer immunotherapy , 2018, Journal of Immunotherapy for Cancer.

[140]  Min Zhang,et al.  MMP-2 and MMP-9 contribute to the angiogenic effect produced by hypoxia/15-HETE in pulmonary endothelial cells. , 2018, Journal of molecular and cellular cardiology.

[141]  E. Hammond,et al.  Challenges to DNA replication in hypoxic conditions , 2018, The FEBS journal.

[142]  P. Boutros,et al.  Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer , 2018, EBioMedicine.

[143]  M. Gandhi,et al.  Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. , 2018, Blood.

[144]  Meijuan Huang,et al.  Activated pancreatic stellate cells inhibit NK cell function in the human pancreatic cancer microenvironment , 2018, Cellular & Molecular Immunology.

[145]  Inna Kuperstein,et al.  Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. , 2018, Cancer cell.

[146]  Linda Ziani,et al.  Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts , 2018, Front. Immunol..

[147]  Hideo Baba,et al.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.

[148]  Soyoung Lee,et al.  Senescence-associated reprogramming promotes cancer stemness , 2017, Nature.

[149]  Ananya Choudhury,et al.  Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts , 2017, Oncotarget.

[150]  Y. Surh,et al.  Hypoxia induces epithelial-mesenchymal transition in colorectal cancer cells through ubiquitin-specific protease 47-mediated stabilization of Snail: A potential role of Sox9 , 2017, Scientific Reports.

[151]  S. Terry,et al.  Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3 , 2017, Oncotarget.

[152]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[153]  J. Ryś,et al.  Podoplanin increases the migration of human fibroblasts and affects the endothelial cell network formation: A possible role for cancer-associated fibroblasts in breast cancer progression , 2017, PloS one.

[154]  C. Kieda,et al.  Abstract 1460: miRNome analyses reveal that activity of CAF expressed podoplanin in tumor microenvironment is modulated by exosome miRNAs involved in the PTEN-PI3K-AKT-mTOR signaling , 2017 .

[155]  T. Sarna,et al.  A 3D model of tumour angiogenic microenvironment to monitor hypoxia effects on cell interactions and cancer stem cell selection. , 2017, Cancer letters.

[156]  Rachel N. Rattenni,et al.  Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas. , 2017, The American journal of pathology.

[157]  C. Domene,et al.  Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication , 2017, Molecular cell.

[158]  Ananya Choudhury,et al.  A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients , 2017, Clinical Cancer Research.

[159]  W. Fan,et al.  Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer , 2017, Cell Death & Disease.

[160]  S. Chouaib,et al.  Tumor hypoxia modulates podoplanin/CCL21 interactions in CCR7+ NK cell recruitment and CCR7+ tumor cell mobilization , 2017, Oncotarget.

[161]  M. Khaled,et al.  Cutting Edge: NANOG Activates Autophagy under Hypoxic Stress by Binding to BNIP3L Promoter , 2017, The Journal of Immunology.

[162]  P. Carmeliet,et al.  Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis. , 2016, Cell metabolism.

[163]  S. Haferkamp,et al.  LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. , 2016, Cell metabolism.

[164]  R. Stupp,et al.  Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial , 2016, BMC Cancer.

[165]  M. Mazzone,et al.  The impact of hypoxia on tumor-associated macrophages. , 2016, The Journal of clinical investigation.

[166]  J. Marescaux,et al.  Development of a methodology for in vivo follow-up of hepatocellular carcinoma in hepatocyte specific Trim24-null mice treated with myo-inositol trispyrophosphate , 2016, Journal of Experimental & Clinical Cancer Research.

[167]  K. Gardner,et al.  Targeting renal cell carcinoma with a HIF-2 antagonist , 2016, Nature.

[168]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[169]  E. Kachaylo,et al.  Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate , 2016, Clinical Cancer Research.

[170]  D. Ferrari,et al.  Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment , 2016, Oncoimmunology.

[171]  C. Gaggioli,et al.  Fibroblast activation in cancer: when seed fertilizes soil , 2016, Cell and Tissue Research.

[172]  Emma Gordon,et al.  Mechanisms and regulation of endothelial VEGF receptor signalling , 2016, Nature Reviews Molecular Cell Biology.

[173]  Jens Overgaard,et al.  Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials , 2016, Acta oncologica.

[174]  L. Dassa,et al.  Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL , 2016, Nature Communications.

[175]  A. Ohta.  A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment , 2016, Front. Immunol..

[176]  H. Lyng,et al.  Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer , 2016, Clinical Cancer Research.

[177]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[178]  A. Pezeshki,et al.  Naturally occurring p16Ink4a-positive cells shorten healthy lifespan , 2016, Nature.

[179]  G. Collet,et al.  Endothelial precursor cell-based therapy to target the pathologic angiogenesis and compensate tumor hypoxia. , 2016, Cancer letters.

[180]  M. Caputo,et al.  Chronic hypoxia down‐regulates tight junction protein ZO‐2 expression in children with cyanotic congenital heart defect , 2015, ESC heart failure.

[181]  N. Sharpless,et al.  Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice , 2015, Nature Medicine.

[182]  Xin-yang Wang,et al.  Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling , 2015, International journal of oncology.

[183]  G. Charras,et al.  Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis , 2015, EMBO reports.

[184]  P. Pandolfi,et al.  PTEN mediates Notch-dependent stalk cell arrest in angiogenesis , 2015, Nature Communications.

[185]  G. Berchem,et al.  Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer , 2015, Oncoimmunology.

[186]  Meiyan Wu,et al.  HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer , 2015, PloS one.

[187]  C. Elly,et al.  E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity. , 2015, Immunity.

[188]  M. Zeisberg,et al.  Snail Is a Direct Target of Hypoxia-inducible Factor 1α (HIF1α) in Hypoxia-induced Endothelial to Mesenchymal Transition of Human Coronary Endothelial Cells* , 2015, The Journal of Biological Chemistry.

[189]  J. Pastorek,et al.  Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. , 2015, Seminars in cancer biology.

[190]  B. Janji,et al.  The autophagy sensor ITPR1 protects renal carcinoma cells from NK-mediated killing. , 2015, Autophagy.

[191]  D. Olive,et al.  ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy. , 2014, Cancer research.

[192]  Z. Werb,et al.  Remodelling the extracellular matrix in development and disease , 2014, Nature Reviews Molecular Cell Biology.

[193]  Qi Zhang,et al.  Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: a meta-analysis. , 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[194]  M. Wolter,et al.  MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape , 2014, Oncotarget.

[195]  M. Aprahamian,et al.  Myo‐inositol trispyrophosphate‐mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy , 2014, International journal of cancer.

[196]  Jingyan Xie,et al.  Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression , 2014, Cellular and Molecular Immunology.

[197]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[198]  Clara Alsinet,et al.  VEGF signaling in cancer treatment. , 2014, Current pharmaceutical design.

[199]  R. Raja,et al.  Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis , 2014, Oncogene.

[200]  C. Graham,et al.  A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. , 2014, Cancer research.

[201]  S. McKeown,et al.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. , 2014, The British journal of radiology.

[202]  G. Semenza.  Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. , 2014, Annual review of pathology.

[203]  Jun Xie,et al.  Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25. , 2014, Experimental cell research.

[204]  E. Hammond,et al.  ATM activation in hypoxia - causes and consequences , 2014, Molecular & cellular oncology.

[205]  G. Berchem,et al.  Autophagic degradation of GZMB/granzyme B , 2014, Autophagy.

[206]  A. Ryan,et al.  Replication Stress and Chromatin Context Link ATM Activation to a Role in DNA Replication , 2013, Molecular cell.

[207]  M. Mazzone,et al.  Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. , 2013, Cancer cell.

[208]  G. Collet,et al.  Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth , 2013, Molecular Cancer Therapeutics.

[209]  H. Moses,et al.  The roles of TGFβ in the tumour microenvironment , 2013, Nature Reviews Cancer.

[210]  J. Zimmer,et al.  Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia , 2013, Proceedings of the National Academy of Sciences.

[211]  L. Moretta,et al.  Hypoxia downregulates the expression of activating receptors involved in NK‐cell‐mediated target cell killing without affecting ADCC , 2013, European journal of immunology.

[212]  C. Muller,et al.  ATR controls cellular adaptation to hypoxia through positive regulation of hypoxia-inducible factor 1 (HIF-1) expression , 2013, Oncogene.

[213]  M. Aprahamian,et al.  Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2 , 2013, Oncogene.

[214]  K. Pacak,et al.  Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. , 2013, Journal of the National Cancer Institute.

[215]  M. Maggiolini,et al.  HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs) , 2013, Breast Cancer Research.

[216]  G. Collet,et al.  Trojan horse at cellular level for tumor gene therapies. , 2013, Gene.

[217]  Z. Husain,et al.  Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells , 2013, The Journal of Immunology.

[218]  Wei Liu,et al.  Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity , 2013, Medical Oncology.

[219]  Crispin J. Miller,et al.  A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer , 2013, Clinical Cancer Research.

[220]  K. Rouschop,et al.  Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells , 2013, PloS one.

[221]  Gang Ding,et al.  HIF1‐regulated ATRIP expression is required for hypoxia induced ATR activation , 2013, FEBS letters.

[222]  R. Wenger,et al.  HIF mediated and DNA damage independent histone H2AX phosphorylation in chronic hypoxia , 2013, Biological chemistry.

[223]  G. Collet,et al.  Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment , 2013, Journal of Molecular Medicine.

[224]  G. Semenza.  Blood vessels, disease pathogenesis, and novel therapies , 2013, Journal of Molecular Medicine.

[225]  Y. Kanai,et al.  Arginase II Expressed in Cancer-Associated Fibroblasts Indicates Tissue Hypoxia and Predicts Poor Outcome in Patients with Pancreatic Cancer , 2013, PloS one.

[226]  A. Santoni,et al.  NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses , 2013, Front. Immun..

[227]  H. Okamura,et al.  Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner. , 2012, International journal of oncology.

[228]  B. Bao,et al.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. , 2012, Biochimica et biophysica acta.

[229]  E. Giannoni,et al.  Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness. , 2012, Cancer letters.

[230]  P. Romero,et al.  Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. , 2012, Cancer research.

[231]  Shih-Chieh Lin,et al.  Hypoxia-induced microRNA-20a expression increases ERK phosphorylation and angiogenic gene expression in endometriotic stromal cells. , 2012, The Journal of clinical endocrinology and metabolism.

[232]  Wei Liu,et al.  Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. , 2012, Cancer letters.

[233]  G. Collet,et al.  Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation. , 2012, Vascular pharmacology.

[234]  Dai Fukumura,et al.  Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology , 2012, Proceedings of the National Academy of Sciences.

[235]  G. Berchem,et al.  Hypoxia-induced autophagy , 2012, Autophagy.

[236]  Alberto Mantovani,et al.  Macrophage plasticity and polarization: in vivo veritas. , 2012, The Journal of clinical investigation.

[237]  T. Cotechini,et al.  Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. , 2011, Cancer research.

[238]  P. Romero,et al.  Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. , 2011, Cancer research.

[239]  B. S. Sørensen,et al.  Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. , 2011, Cancer research.

[240]  D. Biard,et al.  A DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia , 2011, Journal of Cell Science.

[241]  C. Kieda,et al.  Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia , 2011, Journal of cellular and molecular medicine.

[242]  J. Marescaux,et al.  Myo‐InositolTrisPyroPhosphate Treatment Leads to HIF‐1α Suppression and Eradication of Early Hepatoma Tumors in Rats , 2011, Chembiochem : a European journal of chemical biology.

[243]  S. Green,et al.  A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination , 2011, Cancer Chemotherapy and Pharmacology.

[244]  D. Siemann,et al.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. , 2011, Cancer treatment reviews.

[245]  C. Marsh,et al.  Opposing roles for HIF-1α and HIF-2α in the regulation of angiogenesis by mononuclear phagocytes. , 2011, Blood.

[246]  J. Lehn,et al.  myo‐Inositol Trispyrophosphate: A Novel Allosteric Effector of Hemoglobin with High Permeation Selectivity across the Red Blood Cell Plasma Membrane , 2010, Chembiochem : a European journal of chemical biology.

[247]  T. Padhya,et al.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment , 2010, The Journal of experimental medicine.

[248]  M. Kaeberlein,et al.  The hypoxia-inducible factor HIF-1 functions as both a positive and negative modulator of aging , 2010, Biological chemistry.

[249]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[250]  H. H. Marti,et al.  Matrix Metalloproteinase-9 Mediates Hypoxia-Induced Vascular Leakage in the Brain via Tight Junction Rearrangement , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[251]  M. Shackleton.  Normal stem cells and cancer stem cells: similar and different. , 2010, Seminars in cancer biology.

[252]  A. Hoffmann,et al.  Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. , 2010, Genes & development.

[253]  S. Germain,et al.  Hypoxia-driven angiogenesis: role of tip cells and extracellular matrix scaffolding , 2010, Current opinion in hematology.

[254]  P. Queirolo,et al.  Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[255]  A. Harris,et al.  Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. , 2009, Blood.

[256]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[257]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[258]  I. Melero,et al.  Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. , 2008, Trends in pharmacological sciences.

[259]  R. Maestro,et al.  Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. , 2008, Cancer cell.

[260]  J. Fleming,et al.  Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. , 2008, Cancer research.

[261]  Kou-Juey Wu,et al.  Direct regulation of TWIST by HIF-1α promotes metastasis , 2008, Nature Cell Biology.

[262]  A. Sica,et al.  Plasticity of Macrophage Function during Tumor Progression: Regulation by Distinct Molecular Mechanisms1 , 2008, The Journal of Immunology.

[263]  D. Kirkpatrick,et al.  Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α , 2008, Molecular Cancer Therapeutics.

[264]  Dominique Dunon,et al.  Dual Role of Melanoma Cell Adhesion Molecule (MCAM)/CD146 in Lymphocyte Endothelium Interaction: MCAM/CD146 Promotes Rolling via Microvilli Induction in Lymphocyte and Is an Endothelial Adhesion Receptor1 , 2007, The Journal of Immunology.

[265]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[266]  Michael Höckel,et al.  Detection and characterization of tumor hypoxia using pO2 histography. , 2007, Antioxidants & redox signaling.

[267]  Brian Keith,et al.  Hypoxia-Inducible Factors, Stem Cells, and Cancer , 2007, Cell.

[268]  P. Moreau,et al.  Hypoxia modulates HLA-G gene expression in tumor cells. , 2007, Human immunology.

[269]  T. Ohtsuka,et al.  Tumor–stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c‐Met pathway , 2006, International journal of cancer.

[270]  R. Wenger,et al.  Cutting Edge: Hypoxia-Inducible Factor 1α and Its Activation-Inducible Short Isoform I.1 Negatively Regulate Functions of CD4+ and CD8+ T Lymphocytes , 2006, The Journal of Immunology.

[271]  K. Neurath,et al.  Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation , 2006, Oncogene.

[272]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[273]  M. Reed,et al.  Macrophages promote angiogenesis in human breast tumour spheroids in vivo , 2005, British Journal of Cancer.

[274]  C. Lewis,et al.  Hypoxia Regulates Macrophage Functions in Inflammation1 , 2005, The Journal of Immunology.

[275]  Patrick H. Maxwell,et al.  Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.

[276]  R. Weinberg,et al.  The signals and pathways activating cellular senescence. , 2005, The international journal of biochemistry & cell biology.

[277]  A. Buck,et al.  Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. , 2005, Gastroenterology.

[278]  J. Lehn,et al.  Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. , 2005, Bioorganic & medicinal chemistry letters.

[279]  C. Brinckerhoff,et al.  Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinoma , 2005, Oncogene.

[280]  A. Giaccia,et al.  Inhibition of ATR Leads to Increased Sensitivity to Hypoxia/Reoxygenation , 2004, Cancer Research.

[281]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[282]  D. Raulet.  Roles of the NKG2D immunoreceptor and its ligands , 2003, Nature Reviews Immunology.

[283]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[284]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[285]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[286]  S. Colgan,et al.  Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. , 2002, The Journal of clinical investigation.

[287]  H. Bitterman,et al.  Regulation of Endothelial Matrix Metalloproteinase-2 by Hypoxia/Reoxygenation , 2002, Circulation research.

[288]  R K Jain,et al.  Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. , 2001, Cancer research.

[289]  S. White,et al.  HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[290]  J. Norman,et al.  Hypoxia promotes fibrogenesis in human renal fibroblasts. , 2000, Kidney international.

[291]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[292]  M. Monsigny,et al.  Selective induction of peripheral and mucosal endothelial cell addressins with peripheral lymph nodes and Peyer's patch cell‐conditioned media , 1996, Journal of leukocyte biology.

[293]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[294]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[295]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[296]  H. Lederman,et al.  Effects of hypoxia on interleukin‐2 mRNA expression by T lymphocytes , 1994, Critical care medicine.

[297]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[298]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[299]  G. Fleuren,et al.  Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[300]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[301]  Ziying Han,et al.  Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application. , 2021, American journal of cancer research.

[302]  A. Giaccia,et al.  Role of carcinoma-associated fibroblasts and hypoxia in tumor progression. , 2010, Current topics in microbiology and immunology.

[303]  Yong-mei Yang,et al.  Hypoxia induces T-cell apoptosis by inhibiting chemokine C receptor 7 expression: the role of adenosine receptor A2 , 2010, Cellular and Molecular Immunology.

[304]  M. Monsigny,et al.  New human microvascular endothelial cell lines with specific adhesion molecules phenotypes. , 2002, Endothelium : journal of endothelial cell research.